Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03568630 · ClinicalTrials.gov registry record

Blood Markers of Early Pancreas Cancer

A clinical trial of Diabetes Mellitus, Type 2 and PreDiabetes, sponsored by University of Nebraska.

Recruiting
Registry status
1,250
Enrollment target
1
Study location

NCT03568630: Recruiting study of Diabetes Mellitus, Type 2 and PreDiabetes, sponsored by University of Nebraska.

NCT03568630 is a study of Diabetes Mellitus, Type 2 and PreDiabetes that is actively recruiting participants, run by University of Nebraska. The registered enrollment target is 1,250 participants, below the 4,482-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03568630, a study of Diabetes Mellitus, Type 2 and PreDiabetes, is actively recruiting participants, sponsored by University of Nebraska.

RECRUITING
Registry status
1,250 participants
Enrollment target
1
Study location

Study Summary

Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. The investigators propose a longitudinal study of subjects at higher than average risk of PDAC in order to generate clinical data and bank serial blood specimens.

Primary Outcome

Number of pancreas cancer cases diagnosed.

Conditions Studied

Diabetes Mellitus, Type 2 PreDiabetes Chronic Pancreatitis Genetic Predisposition to Disease Pancreas Cyst Inherited Disease

Study Locations (1)

Nebraska

  • Unversity of Nebraska Medical Center - Omaha

Trial Details

FieldValue
Enrollment Target 1,250 participants
Start Date 2018-07-26
Est. Completion 2028-07
University of Nebraska

407 total trials

What NCT03568630 shows while recruiting

NCT03568630 is an observational study that tracks outcomes without assigning an intervention. Its 1,250 participants enrollment target places it among the larger protocols in the corpus, below the 4,482-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (72% lower).

The record links to 6 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 0 interventions.

NCT03568630 reports a single indexed study location in Nebraska.

Frequently Asked Questions

What is clinical trial NCT03568630 about?

NCT03568630 is a clinical study titled "Blood Markers of Early Pancreas Cancer". Identifying biomarkers of early pancreatic ductal adenocarcinoma (PDAC) could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. The investigators propose...

What is the current status of trial NCT03568630?

This trial is currently recruiting. The enrollment target is 1,250 participants. The study started on 2018-07-26. Estimated completion is 2028-07.

What conditions does trial NCT03568630 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, PreDiabetes, Chronic Pancreatitis, Genetic Predisposition to Disease, Pancreas Cyst.

Who is sponsoring clinical trial NCT03568630?

This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03568630 being conducted?

This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03568630's enrollment target sits among peer trials

1,250 25th of 348 higher than 323 of 348 other Diabetes Mellitus, Type 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02743858 · 1,250 participants

    Lymphedema Surveillance Study

  • NCT04670874 · 1,250 participants

    Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29

  • NCT04807868 · 1,250 participants

    AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)

  • NCT05995821 · 1,250 participants

    Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT03568630

Source: ClinicalTrials.gov NCT03568630, the US trial registry maintained by the National Library of Medicine. NCT03568630 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.